Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis

OBJECTIVES: To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromboembolic events. METHODS: This analysis included...

Descripción completa

Detalles Bibliográficos
Autores principales: Morand, Eric, Smolen, Josef S, Petri, Michelle, Tanaka, Yoshiya, Silk, Maria, Dickson, Christina, Meszaros, Gabriella, de la Torre, Inmaculada, Issa, Maher, Zhang, Hong, Dörner, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445377/
https://www.ncbi.nlm.nih.gov/pubmed/37604638
http://dx.doi.org/10.1136/rmdopen-2023-003302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445377/
https://www.ncbi.nlm.nih.gov/pubmed/37604638
http://dx.doi.org/10.1136/rmdopen-2023-003302

Ejemplares similares